03 · What You Need to Know
How to Respond When New Risk Information Emerges
Research Approval Is Based on What Is Known at the Time
Ethics review evaluates a protocol using available evidence about anticipated risks, burdens, benefits, safeguards, and scientific value. That assessment is necessarily provisional because research may generate new information.
The 2024 Declaration of Helsinki requires risks and burdens to be continuously monitored, assessed, and documented after research begins. It also states that when risks and burdens are found to outweigh potential benefits, researchers must immediately assess whether the research should continue, be modified, or be stopped.
Ethical approval is therefore not a permanent declaration that the original risk estimate will remain correct.
A New Risk Is Not the Same as Any Adverse Event
Participants can experience illnesses, injuries, distress, or other negative events during a study for reasons unrelated to the research. Conversely, an event that causes no actual injury may reveal a previously unrecognized research hazard.
Under OHRP guidance for HHS-regulated research, an “unanticipated problem involving risks to subjects or others” generally has three features: it is unexpected in nature, severity, or frequency; it is related or possibly related to research participation; and it suggests that the research places participants or others at greater risk than was previously known or recognized.
Adverse event
An unfavorable occurrence in a participant; it is not necessarily caused by the research or evidence of a newly recognized risk.
Newly recognized research risk
Information indicating that participation may create a type, severity, or frequency of harm not adequately reflected in the previous assessment.
Terminology and reporting definitions vary among jurisdictions and regulatory systems. Researchers should therefore use the definitions and reporting procedures applicable to their study rather than assuming that every negative event receives the same classification.
New Risk Information Can Come From More Than Participant Injury
A new risk may become apparent through an actual adverse event, but that is only one route.
Researchers might discover a data-security vulnerability, receive a safety alert from a sponsor, observe unexpectedly frequent participant distress, learn about an adverse event at another study site, receive new laboratory findings, or encounter external evidence changing what is known about an intervention.
OHRP's framework explicitly recognizes that unanticipated problems need not themselves be adverse events. An incident can reveal greater risk even when no participant has yet suffered detectable harm.
Immediate Participant Protection Comes Before Administrative Convenience
If new information indicates an apparent immediate hazard, the first responsibility is to protect participants.
For research under the U.S. Common Rule, OHRP notes that changes ordinarily require IRB review before implementation, except when changes are necessary to eliminate apparent immediate hazards to participants. Its guidance identifies such immediate protective changes as one possible response to an unanticipated problem.
The precise authority and procedure depend on the applicable framework. Researchers should know in advance whom to contact and what emergency actions their protocol, institution, sponsor, and ethics committee permit.
Watch Out
Do not delay an action necessary to address an apparent immediate hazard merely because a routine amendment has not yet completed review. At the same time, emergency changes should not become a convenient route around required ethics approval; follow the applicable reporting and review procedures promptly afterward.
Ask Whether the New Information Changes Nature, Severity, or Frequency
A known risk can become newly important without being entirely new.
Suppose mild liver effects were anticipated, but a participant develops severe liver failure plausibly related to the study intervention. The category of harm may not be completely unfamiliar, yet its severity is different from what was previously recognized.
Likewise, a complication expected in 5% of participants may require reassessment if monitoring shows it occurring in half of participants. OHRP's guidance explicitly treats unexpected severity or frequency as potentially relevant to determining whether an event represents an unanticipated problem.
Investigate Causality Without Waiting for Impossible Certainty
Researchers should examine whether the new event or information is related to the research. That assessment may require clinical evaluation, temporal relationships, dechallenge or rechallenge information where appropriate, alternative explanations, data from other participants, sponsor information, or external evidence.
Absolute proof is not always available. OHRP uses the category “related or possibly related,” defining possibly related as a reasonable possibility that the research procedures caused the incident, experience, or outcome.
The practical lesson extends beyond that specific regulatory framework: participant protection should not depend on pretending that uncertainty is the same as no relationship.
Look for Patterns, Not Just Dramatic Single Events
Some new risks emerge gradually.
One participant reporting unexpected distress may warrant investigation. Ten participants reporting the same previously unrecognized reaction may reveal a pattern. A known adverse event occurring far more frequently than predicted may also change the risk profile.
Monitoring systems should therefore allow researchers to see aggregated patterns rather than evaluating every event as though nothing else has happened.
Reassess the Existing Safeguards
Once a new risk is credible, ask whether existing protections remain adequate.
OHRP lists several possible corrective actions for unanticipated problems: modifying inclusion or exclusion criteria, adding monitoring, suspending enrollment, suspending procedures in currently enrolled participants, changing the protocol, revising consent documents, and providing enrolled participants with new risk information.
The appropriate response depends on the risk. A new confidentiality concern may require data-security changes rather than clinical monitoring. Unexpected interview distress may require question revision, interviewer training, or response procedures. A serious biological adverse effect may require eligibility changes, laboratory monitoring, dose modification, or suspension.
Report According to the Rules That Govern the Study
Researchers should not assume that every new event follows one universal reporting timeline or destination.
Requirements can depend on jurisdiction, institution, sponsor, funding source, product regulation, study type, and seriousness of the event. Under HHS requirements, for example, institutions must maintain procedures for prompt reporting of unanticipated problems involving risks to participants or others, and OHRP provides guidance on the information such reports should contain.
A useful report ordinarily describes what happened, why it changes or may change the known risk, what has already been done, and what corrective actions are proposed.
Do Not Quietly Change the Protocol Unless Immediate Protection Requires It
Discovering a problem does not normally authorize researchers to redesign an approved protocol independently and continue indefinitely.
OHRP guidance states that proposed changes responding to an unanticipated problem generally require IRB review and approval before implementation, except when necessary to eliminate apparent immediate hazards.
This distinction protects participants while preserving independent oversight. Immediate danger may require immediate action. Non-emergency modifications should ordinarily proceed through the applicable amendment process.
Current Participants May Need the New Information
A participant agreed to a particular research proposition based on the risks and potential benefits known at the time. If that proposition materially changes, their willingness to continue may also change.
OHRP notes that informed consent should be understood as an ongoing process. Significant new findings developed during research that may relate to a participant's willingness to continue should, when appropriate, be provided to the participant. Changes in risk can require supplementation or repetition of the consent process.
This does not mean every minor operational update requires re-consent. The relevant question is whether the information could reasonably affect a participant's understanding or decision about continued participation.
New Participants Need an Accurate Current Risk Description
If recruitment continues after a meaningful new risk is recognized, newly enrolled participants should not receive an outdated description of the study.
Depending on the applicable review process, recruitment may need to pause while the protocol and consent information are updated. In other cases, the ethics committee may permit continuation with specified safeguards.
The underlying principle is straightforward: researchers should not knowingly invite new participants into a study using a risk description that no longer reflects what is known.
Previously Enrolled Participants May Need More Than a New Consent Form
Simply handing someone a revised document can reduce re-consent to paperwork.
If new information is important enough to affect continued participation, researchers should communicate what has changed, what is known and uncertain, whether safeguards or procedures have changed, what options participants have, and what happens if they choose not to continue.
OHRP specifically identifies providing additional information about newly recognized risks to previously enrolled participants as a potential corrective action.
The New Risk May Change the Original Risk-Benefit Balance
A new adverse effect may increase expected harm. New external evidence may reduce expected benefit. Either development can alter the ethical basis for continuation.
The next question is therefore whether the new information changes the original risk-benefit balance. That assessment should consider the new risk together with remaining potential benefits, scientific value, available alternatives, participant circumstances, and safeguards.
Some Situations Justify a Temporary Pause Before the Final Answer Is Known
Researchers sometimes face a genuine uncertainty: the new signal is concerning enough that continuing unchanged may expose participants unnecessarily, but the evidence is not yet sufficient to determine whether the entire study should stop.
Possible responses identified in OHRP guidance include suspending enrollment or suspending research procedures in currently enrolled participants while the problem is evaluated.
A pause is therefore not necessarily an admission that the study was unethical. It can be a participant-protection measure while the evidence is clarified. The separate question of when a changed risk-benefit balance should trigger a study pause depends on the circumstances.
Stopping May Become Necessary
If the new information reveals that risks can no longer be satisfactorily managed or justified, modification may not be enough.
The Declaration of Helsinki requires researchers to immediately assess whether research should continue, be modified, or be stopped when risks and burdens outweigh potential benefits. OHRP also notes IRB authority to suspend or terminate approval of research associated with unexpected serious harm under applicable HHS regulations.
The decision to stop research because participants may be harmed requires attention not only to future recruitment but also to the welfare of people already enrolled.
